CD8A and Patent ductus arteriosus: Thus, the lack of CXCL12–KRT19 coating of PDA cells is directly responsible for the enhanced intratumoral accumulation of activated CD8+ T cells and sensitivity to treatment with anti–PD-1 antibody.